Table 3.

Possible treatments for patients who have received two or more prior lines of therapy.

Treatment of patients who have received two or more prior lines of therapy
Trial	No Prior Lines	Agents	Outcome	References
BOSTON	1–3	Weekly Selinexor-Vd vs. 2 X per week Vd	Median PFS 13.9 months vs. 9.5 months. Less PN with Selinexor-Vd	[29]
APOLLO	2	Dara-POM-d vs. POM-d	Median PFS 12.4 vs. 6.9 months	[27]
ICARIA	3	Isa-POMd vs. POMd	Median PFS 11.5 vs. 6.5 months	[26]
DREAMM-2	3	Belantamab mafadotin 2.5 or 3.4 mg/kg	ORR 31% and 34% Median PFS 2.9 and 4.9 months	[51]
ELOQUENT 3	3	Elotuzumab-POMd vs. POMd	ORR 53% vs. 26% Median PFS 10.3 vs. 4.7 months	[52]
	4	PomCyDex vs. PomDex	Median PFS 9.5 vs. 4.4 months	[48]
STORM	7	Selinexor + dexamethasone	≥PR 26%, median PFS 3.7 months Median OS 8.6 months	[49]

Vd bortezomib + dexamethasone, POMd pomalidomide + dexamethasone.